REQUEST A DEMO
Total
USD $0.00
Search more companies

Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja (Serbia)

Main Activities: Research and Development in Nanotechnology
Full name: Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja Profile Updated: September 30, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja is an enterprise in Serbia, with the main office in Belgrade. It operates in the Research and Development in Nanotechnology sector. The company was established on January 16, 2026. Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja currently employs 151 (2024) people. In 2024, the company reported a net sales revenue increase of 4.14%. During that time, Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja’s total assets grew by 10.92%. In, 2024, the company’s net profit margin increased by 0.75%.

Headquarters
Tadeusa Koscuska 1 1
Belgrade; Belgrade;

Contact Details: Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.

Website: http://www.mocbilja.rs

Basic Information
Total Employees:
Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.
Registered Capital:
Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.
Financial Auditors:
Purchase the Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report to view the information.
Incorporation Date:
January 16, 2026
Key Executives
Purchase this report to view the information.
Legal Representative
Company Performance
Financial values in the chart are available after Dr. Josif Pancic Institut Za Proucavanje Lekovitog Bilja report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
4.14%
Total operating revenue
8.95%
Operating profit (EBIT)
1344.96%
EBITDA
286.07%
Net Profit (Loss) for the Period
2424.47%
Total Assets
10.92%
Total Equity
-15.02%
Operating Profit Margin (ROS)
8.95%
Net Profit Margin
0.75%
Return on Equity (ROE)
2.22%
Debt/Equity
24.08%
Quick Ratio
-0.38%
Cash Ratio
0.01%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?